JPH08337521A - Percutaneous drug-releasing device - Google Patents
Percutaneous drug-releasing deviceInfo
- Publication number
- JPH08337521A JPH08337521A JP7147603A JP14760395A JPH08337521A JP H08337521 A JPH08337521 A JP H08337521A JP 7147603 A JP7147603 A JP 7147603A JP 14760395 A JP14760395 A JP 14760395A JP H08337521 A JPH08337521 A JP H08337521A
- Authority
- JP
- Japan
- Prior art keywords
- drug
- time delay
- film
- delay control
- time
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、種々の治療剤や診断剤
を皮膚吸収する際に用いられる経皮薬剤放出デバイスに
関するものである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a transdermal drug delivery device used for skin absorption of various therapeutic agents and diagnostic agents.
【０００２】[0002]
【従来の技術】経皮吸収製剤は、一定速度放出型の製剤
が、ニトログリセリン、スコポラミン、エストラジオー
ル、硝酸イソソルビド、フェンタニル、クロニジン、ニ
コチンなどに臨床利用されている。また、これらの治療
薬ばかりでなく、一般に経皮治療可能な薬剤には、現在
開発されている長期間一定放出型の経皮吸収製剤も用い
られている。2. Description of the Related Art As a percutaneous absorption preparation, a constant rate release preparation is clinically used for nitroglycerin, scopolamine, estradiol, isosorbide nitrate, fentanyl, clonidine, nicotine and the like. In addition to these therapeutic agents, transdermal therapeutic preparations of long-term constant release type that are currently being developed are also used for drugs that can be transdermally treated.
【０００３】[0003]
【発明が解決しようとする課題】しかしながら、このよ
うな長期間一定放出型の経皮吸収製剤では耐性が現れた
り、耐性防止のため増量投与によって副作用が無視でき
なくなることが問題となっている。特に、ニトログリセ
リンやニコチンの経皮吸収治療では耐性防止型の経皮吸
収治療製剤が望まれている。However, in such a long-term constant release type transdermal absorption preparation, such a long-term constant release type has a problem in that resistance appears, and side effects cannot be ignored by increasing the dose to prevent resistance. In particular, in the percutaneous absorption treatment of nitroglycerin and nicotine, a percutaneous absorption therapeutic preparation of a resistance type is desired.
【０００４】本発明は、上記状況に鑑みて、時間遅れ制
御膜によって薬理学的に活性な剤を所定の調整された速
度と時間遅れで放出し、治療時間の調整または多回連続
治療における耐性の防止を図ることができる治療時間の
調節が可能な経皮薬剤放出デバイスを提供することを目
的とする。In view of the above situation, the present invention releases a pharmacologically active agent by a time delay control membrane at a predetermined adjusted rate and time delay, and adjusts the treatment time or resistance in multiple continuous treatments. It is an object of the present invention to provide a transdermal drug delivery device capable of controlling treatment time capable of preventing the above.
【０００５】[0005]
【課題を解決するための手段】本発明は、上記目的を達
成するために、 （１）経皮薬剤放出デバイスにおいて、薬理学的に活性
な剤を含む薬剤保存層本体と、薬剤保存層に接着される
透過性時間遅れ制御膜が不透過分離膜で分離された多層
膜経皮吸収製剤で、使用直前に前記不透過分離膜のみを
取り除き前記薬剤保存層に時間遅れ制御膜を接着するこ
とによって、前記薬剤保存層からの薬剤の放出を一定時
間停止し得るようにしたものである。In order to achieve the above object, the present invention provides (1) a transdermal drug delivery device comprising a drug storage layer body containing a pharmacologically active agent, and a drug storage layer. Permeability time delay control film to be adhered is a multi-layered transdermal absorption preparation in which a time permeable control film is separated by an impermeable separation film, and only the impermeable separation film is removed immediately before use to adhere the time delay control film to the drug storage layer. Thus, the release of the drug from the drug storage layer can be stopped for a certain period of time.
【０００６】（２）上記（１）記載の経皮薬剤放出デバ
イスにおいて、前記薬剤保存層および透過性時間遅れ制
御膜には透過促進剤を含ませることができるようにした
ものである。 （３）上記（１）記載の経皮薬剤放出デバイスにおい
て、前記薬理学的に活性な剤として全身作用の治療剤を
用いるようにしたものである。(2) In the transdermal drug-releasing device described in (1) above, a permeation enhancer can be contained in the drug storage layer and the permeation time delay control film. (3) In the transdermal drug delivery device according to (1) above, a therapeutic agent having a systemic effect is used as the pharmacologically active agent.
【０００７】（４）上記（１）記載の経皮薬剤放出デバ
イスにおいて、前記薬理学的に活性な剤として局所作用
の治療剤を用いるようにしたものである。 （５）上記（１）記載の経皮薬剤放出デバイスにおい
て、前記薬理学的に活性な剤として診断剤を用いるよう
にしたものである。 （６）上記（１）乃至（５）のうちいずれか１項記載の
経皮薬剤放出デバイスにおいて、前記透過性時間遅れ制
御膜として脂溶性合成高分子膜を用いるようにしたもの
である。(4) In the transdermal drug delivery device described in (1) above, a therapeutic agent having a local action is used as the pharmacologically active agent. (5) In the transdermal drug delivery device according to (1) above, a diagnostic agent is used as the pharmacologically active agent. (6) In the transdermal drug delivery device according to any one of (1) to (5) above, a fat-soluble synthetic polymer film is used as the permeability time delay control film.
【０００８】（７）上記（１）乃至（５）のうちいずれ
か１項記載の経皮薬剤放出デバイスにおいて、前記透過
性時間遅れ制御膜として親水性合成高分子膜を用いるよ
うにしたものである。 （８）上記（１）乃至（５）のうちいずれか１項記載の
経皮薬剤放出デバイスにおいて、前記透過性時間遅れ制
御膜として２層以上の高分子膜を用いるようにしたもの
である。(7) In the transdermal drug delivery device according to any one of (1) to (5) above, a hydrophilic synthetic polymer film is used as the permeability time delay control film. is there. (8) In the transdermal drug delivery device according to any one of (1) to (5), two or more polymer films are used as the permeability time delay control film.
【０００９】[0009]
【作用】本発明によれば、経皮薬剤放出デバイスにおい
て、使用までは、薬理学的に活性な剤を含んだ薬剤保存
層本体（２）と透過性の時間遅れ制御膜（６）が不透過
分離膜（４）を介して構成されており、使用直前にその
不透過分離膜（４）を取り除き、前記薬剤保存層本体
（２）と時間遅れ制御膜（６）を接着したのち、時間遅
れ制御膜（６）の粘着層（５）を皮膚に張りつける。放
出速度が定常になるまでの時間遅れは、時間遅れ制御膜
（６）内の拡散係数と膜厚みに依存するので、膜の内部
構造と膜厚みの制御によって、時間遅れが任意に調節で
きる。According to the present invention, in the transdermal drug delivery device, the drug storage layer body (2) containing the pharmacologically active agent and the permeable time delay control membrane (6) are not used until use. Immediately before use, the impermeable separation film (4) is removed, and the drug storage layer body (2) and the time delay control film (6) are adhered to each other. The adhesive layer (5) of the delay control film (6) is attached to the skin. Since the time delay until the release rate becomes steady depends on the diffusion coefficient and the film thickness in the time delay control film (6), the time delay can be arbitrarily adjusted by controlling the internal structure of the film and the film thickness.
【００１０】したがって、夜睡眠前に張りつけて、翌朝
から治療を開始できたり、連続多回使用において、薬物
を放出しない治療休止期間を設定でき、耐性の防止が可
能になる。Therefore, the treatment can be started from the next morning by sticking before sleep at night, and a treatment rest period in which the drug is not released can be set in continuous multiple use, and tolerance can be prevented.
【００１１】[0011]
【実施例】以下、本発明の実施例について図面を参照し
ながら説明する。図１は本発明の実施例を示す薬剤の経
皮放出デバイスの一例を示す図である。図１（ａ）に示
すように、高分子基材の薬剤保存層本体２に薬理学的に
活性な剤（薬剤）が分散しており、不透過パッキング膜
１で環境条件から保護されている。その下部に粘着層３
が付加されている。なお、薬物保存層が粘着性のある高
分子基材である場合には粘着層３は付加しなくてもよ
い。薬剤保存層本体２と透過性の時間遅れ制御膜６は取
り除き可能な不透過薄膜からなる不透過分離膜４で分離
されている。Embodiments of the present invention will be described below with reference to the drawings. FIG. 1 is a diagram showing an example of a transdermal drug delivery device showing an embodiment of the present invention. As shown in FIG. 1 (a), a pharmacologically active agent (drug) is dispersed in a polymer-based drug storage layer body 2 and is protected from environmental conditions by an impermeable packing film 1. . Adhesive layer 3 underneath
Is added. When the drug storage layer is a polymer base material having an adhesive property, the adhesive layer 3 may not be added. The drug storage layer body 2 and the permeable time delay control film 6 are separated by an impermeable separation film 4 composed of a removable impermeable thin film.
【００１２】次に、図１（ｂ）に示すように、その不透
過分離膜４を使用直前に本体デバイスより取り離し、図
１（ｃ）に示すように、リリースライナー７を取り離
し、粘着層５によって皮膚表面へ張り付ける。粘着層３
及び５は必要に応じて付加されるが、粘着層中の透過抵
抗は無視できる。薬剤放出の時間遅れは、時間遅れ制御
膜６の内部構造と厚みによって任意に調節できる。薬剤
保存層本体２は、高分子基材中に薬剤を粒子状、結晶
状、液滴状あるいは溶解状に含んでいるマトリックスも
しくはレザバー型の保存層である。Next, as shown in FIG. 1 (b), the impermeable separation membrane 4 is separated from the main body device immediately before use, and as shown in FIG. 1 (c), the release liner 7 is separated and adhered. It is applied to the skin surface by means of layer 5. Adhesive layer 3
Although 5 and 5 are added as required, the permeation resistance in the adhesive layer can be ignored. The time delay of drug release can be arbitrarily adjusted by the internal structure and thickness of the time delay control film 6. The drug storage layer main body 2 is a matrix or reservoir type storage layer containing a drug in a particulate, crystalline, droplet or dissolved state in a polymer base material.
【００１３】次に、本発明の実施例を用いて例証する
が、本発明の範囲はこれらによって限定されるものでは
ない。 〔実施例１〕ここでは、透過性時間遅れ制御膜としての
ブレンドポリエチレン膜による脂溶性薬剤プロゲストロ
ン放出の時間遅れ制御について説明する。Next, examples of the present invention will be illustrated, but the scope of the present invention is not limited thereto. [Example 1] Here, the time delay control of the release of the fat-soluble drug progesterone by the blend polyethylene film as the permeability time delay control film will be described.
【００１４】薬剤プロゲストロンの放出時間遅れを、低
密度と高密度ポリエチレンのブレンド率の異なる高分子
膜の厚みとブレンド率によって調節できることを確認し
た。低密度ポリエチレン／高密度ポリエチレンブレンド
膜の低密度ポリエチレン比率を１００、８０、６０、４
０、２０および０％に変化させた厚み５０μｍの膜を用
いて親油性薬剤プロゲステロンの透過速度を水平型拡散
セルで測定した。It was confirmed that the release time delay of the drug progesterone can be controlled by the thickness and blending ratio of polymer films having different blending ratios of low density and high density polyethylene. Low density polyethylene ratio of low density polyethylene / high density polyethylene blend membrane is 100, 80, 60, 4
The permeation rate of the lipophilic drug progesterone was measured in a horizontal diffusion cell using a 50 μm thick membrane that was varied to 0, 20 and 0%.
【００１５】その結果、透過の時間遅れは低密度ポリエ
チレンのブレンド比率によって、１時間から２４時間の
範囲に調節できた。また、低密度ポリエチレンの比率が
８０％および４０％のポリマー膜の定常状態透過速度
は、６０％のポリマー膜に比べ５０％程度の差の範囲内
にあり、定常状態透過速度を大きく変化させずに、時間
遅れだけを広範囲に調節できることがわかった。As a result, the time delay of permeation could be adjusted in the range of 1 hour to 24 hours depending on the blending ratio of low density polyethylene. In addition, the steady-state permeation rate of the polymer membranes with low-density polyethylene ratios of 80% and 40% is within a range of about 50% as compared with the polymer membrane of 60%, and the steady-state permeation rate does not change significantly. Moreover, it was found that only the time delay could be adjusted in a wide range.
【００１６】さらに、時間遅れ、膜厚みと拡散係数の関
係、拡散係数＝厚み2 ／（６ｘ時間遅れ）より拡散係数
を求めたところ、拡散係数をブレンド比率によって１０
-11から１０-9ｃｍ2 ／ｓの範囲で調節可能なことが判
明した。厚み５０μｍの膜の場合、時間遅れは１時間か
ら１１６時間（約５日）まで制御可能である。一方、薬
剤のブレンド膜への溶解度は、ブレンド比率にほとんど
依存しないことが明らかになった。Further, the diffusion coefficient was calculated from the time delay, the relationship between the film thickness and the diffusion coefficient, and the diffusion coefficient = thickness 2 / (6 × time delay).
It was found to be adjustable in the range from -11 to 10 -9 cm 2 / s. In the case of a film having a thickness of 50 μm, the time delay can be controlled from 1 hour to 116 hours (about 5 days). On the other hand, it was revealed that the solubility of the drug in the blend film was almost independent of the blend ratio.
【００１７】〔実施例２〕ここでは、透過性時間遅れ制
御膜としてのシリコーンエラストマー膜によるプロゲス
テロン放出の時間遅れ制御について説明する。２０．１
ｇシリコーンエラストマー（ＭＤＸ４−４２１０）、
４．０ｇミリスチン酸イソプロピル（ＩＰＭ）、４．０
ｇプロゲステロン、２．０ｇ架橋剤の混合物にトルエン
２０ｍｌを加え、よく攬拌した後、厚み２００μｍのマ
トリックス型薬剤保存層膜を作製し、摂氏４０度で一昼
夜乾燥した。Example 2 Here, the time delay control of progesterone release by a silicone elastomer film as a permeability time delay control film will be described. 20.1
g silicone elastomer (MDX4-4210),
4.0 g isopropyl myristate (IPM), 4.0
20 ml of toluene was added to a mixture of g progesterone and 2.0 g cross-linking agent, and after stirring well, a 200 μm thick matrix-type drug storage layer film was prepared and dried at 40 ° C. overnight.
【００１８】更に、薬剤を含まないシリコーンエラスト
マー膜を同様の方法で作製し、両面をシリコーンコーテ
ィングした厚み２５μｍのポリエチレンテレフタレート
膜で分離した。薬剤放出実験直前に分離膜を取り除き、
薬物保存層と時間遅れ制御膜を接着し、薬剤放出実験を
行った。時間遅れ制御膜には、厚み１．０ｍｍと２００
μｍのＭＤＸ４−４２１０膜を用いた。その結果、プロ
ゲステロンの時間遅れは、それぞれ８．２時間及び１９
分となった。従って、時間遅れ制御膜の厚みが２００μ
ｍから１．０ｍｍの範囲の調節によって治療開始の時間
遅れを約２０分から８時間程度まで制御できることが明
らかとなった。Further, a silicone elastomer film containing no drug was prepared by the same method and separated by a polyethylene terephthalate film having a thickness of 25 μm, both surfaces of which were coated with silicone. Just before the drug release experiment, remove the separation membrane,
A drug release experiment was carried out by adhering the drug storage layer and the time delay control film. The time delay control film has a thickness of 1.0 mm and 200
A μm MDX4-4210 membrane was used. As a result, the progesterone time delay was 8.2 hours and 19 hours, respectively.
It became a minute. Therefore, the thickness of the time delay control film is 200μ
It became clear that the time delay of the start of treatment can be controlled from about 20 minutes to about 8 hours by adjusting the range from m to 1.0 mm.
【００１９】〔実施例３〕ここでは、透過性時間遅れ制
御膜としての超低密度ポリエチレン膜によるプレドニソ
ロン放出の時間遅れ制御について説明する。２０．１ｇ
シリコーンエラストマー（ＭＤＸ４−４２１０）、４．
０ｇミリスチン酸イソフロピル（ＩＰＭ）、２．０ｇブ
レドニソロン、２．０ｇ架橋剤の混合物にトルエン２０
ｍｌを加え、よく攬拌した後、厚み２００μｍのマトリ
ックス型薬物保存層膜を作製し、摂氏４０度で一昼夜乾
燥した。[Embodiment 3] Here, the time delay control of prednisolone release by an ultra-low density polyethylene film as a permeability time delay control film will be described. 20.1 g
Silicone elastomer (MDX4-4210), 4.
Toluene 20 in a mixture of 0 g isoflopyr myristate (IPM), 2.0 g brednisolone, 2.0 g crosslinker.
After adding ml and stirring well, a matrix type drug storage layer film having a thickness of 200 μm was prepared and dried at 40 ° C. for one day.
【００２０】更に、薬剤を含まない厚み４０及び８０μ
ｍの超低密度ポリエチレン膜を、両面をシリコーンコー
ティングした厚み２５μｍのポリエチレンテレフタレー
ト膜で分離し、多層膜ブレドニソロン製剤を作製した。
薬物放出実験直前に、分離膜を取り除き、薬物保存層と
時間遅れ制御膜を接着し、４０％ポリエチレングリコー
ル４００溶液中への放出実験を行った。その結果、ブレ
ドニソロンの放出時間遅れは、それぞれの時間遅れ制御
膜について２．３時間及び８．２時間になった。Further, the thickness is 40 and 80μ without containing the drug.
The ultra-low density polyethylene film of m was separated by a polyethylene terephthalate film having a thickness of 25 μm, both surfaces of which were coated with silicone, to prepare a multi-layered bradenisolone preparation.
Immediately before the drug release experiment, the separation membrane was removed, the drug storage layer and the time delay control film were adhered, and the release experiment into a 40% polyethylene glycol 400 solution was conducted. As a result, the release time delay of brednisolone was 2.3 hours and 8.2 hours for each time delay control film.
【００２１】上記した経皮薬剤放出デバイスは、使用す
る直前まで薬剤を含まない時間遅れ制御膜に薬物が浸透
するのを防止することによって、薬剤放出の時間遅れを
任意の時間に調節し、デバイスを皮膚表面へ張りつけた
後、薬理効果を発現するまでの時間を調節できる。ま
た、連続的に皮膚に張り付けても、ある一定時間薬剤の
放出しない期間が得られるので、血中や標的組織から薬
剤が消失する治療休止期間を実現でき、長期運用での耐
性を防止できる。The above-mentioned transdermal drug-releasing device adjusts the time delay of drug release to an arbitrary time by preventing the drug from permeating the drug-free time-delay control membrane until just before use. The time until the pharmacological effect is exerted can be adjusted after the is applied to the skin surface. Further, even if the drug is continuously applied to the skin, a period in which the drug is not released can be obtained for a certain period of time, so that a treatment pause period in which the drug disappears from the blood or target tissue can be realized, and resistance in long-term operation can be prevented.
【００２２】なお、本発明は上記実施例に限定されるも
のではなく、本発明の趣旨に基づいて種々の変形が可能
であり、これらを本発明の範囲から排除するものではな
い。The present invention is not limited to the above embodiments, and various modifications can be made based on the spirit of the present invention, and these modifications are not excluded from the scope of the present invention.
【００２３】[0023]
【発明の効果】以上、詳細に説明したように、本発明に
よれば、次のような効果を奏することができる。経皮薬
剤放出デバイスにおいて、使用までは、薬理学的に活性
な剤を含んだ薬剤保存膜と透過性の時間遅れ制御膜が不
透過分離膜を介して構成されており、使用直前にその不
透過分離膜を取り除き、薬剤保存膜と時間遅れ制御膜を
接着したのち、時間遅れ制御膜の粘着層を皮膚に張りつ
ける。放出速度が定常になるまでの時間遅れは、時間遅
れ制御膜内の拡散係数と膜厚みに依存するので、膜の内
部構造と膜厚みの制御によって、時間遅れが任意に調節
できる。As described in detail above, according to the present invention, the following effects can be obtained. Until use, the transdermal drug delivery device is composed of a drug storage film containing a pharmacologically active agent and a permeable time delay control film via an impermeable separation film. After removing the permeation separation membrane and adhering the drug storage membrane and the time delay control membrane, the adhesive layer of the time delay control membrane is attached to the skin. Since the time delay until the release rate becomes steady depends on the diffusion coefficient and the film thickness in the time delay control film, the time delay can be arbitrarily adjusted by controlling the internal structure of the film and the film thickness.
【００２４】したがって、夜睡眠前に張りつけて翌朝か
ら治療を開始できたり、また、連続的に皮膚に張り付け
ても、ある一定時間薬剤の放出しない期間が得られるの
で、血中や標的組織から薬剤が消失する治療休止期間を
実現でき、長期運用での耐性を防止できる。Therefore, the treatment can be started from the next morning by applying the drug before sleep at night, or even if the drug is continuously applied to the skin, a period in which the drug is not released can be obtained for a certain period of time. It is possible to realize a treatment rest period in which the disappearance occurs, and it is possible to prevent tolerance in long-term operation.
【図１】本発明の実施例を示す治療時間の調節可能な経
皮薬剤放出デバイスの断面図である。FIG. 1 is a cross-sectional view of an adjustable therapeutic time transdermal drug delivery device according to an embodiment of the present invention.
１ 不透過パッキング膜 ２ 薬剤保存層本体 ３，５ 粘着層 ４ 不透過分離膜 ６ 時間遅れ制御膜 ７ リリースライナー 1 Impermeable packing membrane 2 Drug storage layer body 3,5 Adhesive layer 4 Impermeable separation membrane 6 Time delay control membrane 7 Release liner
Claims (8)
体と、薬剤保存層に接着される透過性時間遅れ制御膜が
不透過分離膜で分離された多層膜経皮吸収製剤で、使用
直前に前記不透過分離膜のみを取り除き前記薬剤保存層
に時間遅れ制御膜を接着することによって、前記薬剤保
存層からの薬剤の放出を一定時間停止し得る経皮薬剤放
出デバイス。1. A multi-layered percutaneous absorption preparation in which a drug storage layer body containing a pharmacologically active agent and a permeability time delay control film adhered to the drug storage layer are separated by an impermeable separation film, A transdermal drug delivery device capable of stopping the release of a drug from the drug storage layer for a certain period of time by removing only the impermeable separation film immediately before use and adhering a time delay control film to the drug storage layer.
おいて、前記薬剤保存層および透過性時間遅れ制御膜に
は透過促進剤を含ませることができる経皮薬剤放出デバ
イス。2. The transdermal drug delivery device according to claim 1, wherein the drug storage layer and the permeation time delay control membrane can contain a permeation enhancer.
おいて、前記薬理学的に活性な剤が全身作用の治療剤で
ある経皮薬剤放出デバイス。3. The transdermal drug delivery device of claim 1, wherein the pharmacologically active agent is a systemic therapeutic agent.
おいて、前記薬理学的に活性な剤が局所作用の治療剤で
ある経皮薬剤放出デバイス。4. The transdermal drug delivery device according to claim 1, wherein the pharmacologically active agent is a therapeutic agent for local action.
おいて、前記薬理学的に活性な剤が診断剤である経皮薬
剤放出デバイス。5. The transdermal drug delivery device according to claim 1, wherein the pharmacologically active agent is a diagnostic agent.
の経皮薬剤放出デバイスにおいて、前記透過性時間遅れ
制御膜が脂溶性合成高分子膜である経皮薬剤放出デバイ
ス。6. The transdermal drug delivery device according to claim 1, wherein the permeation time delay control film is a lipophilic synthetic polymer film.
の経皮薬剤放出デバイスにおいて、前記透過性時間遅れ
制御膜が親水性合成高分子膜である経皮薬剤放出デバイ
ス。7. The transdermal drug delivery device according to claim 1, wherein the permeation time delay control film is a hydrophilic synthetic polymer film.
の経皮薬剤放出デバイスにおいて、前記透過性時間遅れ
制御膜が２層以上の高分子膜からなる経皮薬剤放出デバ
イス。8. The transdermal drug-releasing device according to claim 1, wherein the permeability time delay control film comprises a polymer film having two or more layers.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14760395A JP3172395B2 (en) | 1995-06-14 | 1995-06-14 | Transdermal drug release device |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14760395A JP3172395B2 (en) | 1995-06-14 | 1995-06-14 | Transdermal drug release device |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH08337521A true JPH08337521A (en) | 1996-12-24 |
| JP3172395B2 JP3172395B2 (en) | 2001-06-04 |
Family
ID=15434070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP14760395A Expired - Fee Related JP3172395B2 (en) | 1995-06-14 | 1995-06-14 | Transdermal drug release device |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3172395B2 (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6072086A (en) * | 1996-04-12 | 2000-06-06 | Intergen Company | Method and composition for controlling formaldehyde fixation by delayed quenching |
| US6319683B1 (en) | 1996-04-12 | 2001-11-20 | Intergen Company | Method and composition for controlling formaldehyde fixation by delayed quenching |
| WO2010098261A1 (en) * | 2009-02-24 | 2010-09-02 | 久光製薬株式会社 | Risperidone-containing transdermal preparation and adhesive patch using same |
| JP2010248238A (en) * | 2004-01-23 | 2010-11-04 | Travanti Pharma Inc | Abuse potential reduction in abusable substance dosage form |
| GB2485637A (en) * | 2010-11-22 | 2012-05-23 | Dewan Fazlul Hoque Chowdhury | Multi-layered Transdermal Patch activated upon removal of an impermeable inner liner |
| JP2013023271A (en) * | 2011-07-25 | 2013-02-04 | Toppan Printing Co Ltd | Liquid applicator |
| JP2013529100A (en) * | 2010-04-28 | 2013-07-18 | キンバリー クラーク ワールドワイド インコーポレイテッド | Injection mold microneedle array and manufacturing method thereof |
| JP2014005219A (en) * | 2012-06-22 | 2014-01-16 | Teijin Ltd | Sheet-like hemostatic material |
| US11129975B2 (en) | 2011-10-27 | 2021-09-28 | Sorrento Therapeutics, Inc. | Transdermal delivery of high viscosity bioactive agents |
-
1995
- 1995-06-14 JP JP14760395A patent/JP3172395B2/en not_active Expired - Fee Related
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6072086A (en) * | 1996-04-12 | 2000-06-06 | Intergen Company | Method and composition for controlling formaldehyde fixation by delayed quenching |
| US6319683B1 (en) | 1996-04-12 | 2001-11-20 | Intergen Company | Method and composition for controlling formaldehyde fixation by delayed quenching |
| JP2010248238A (en) * | 2004-01-23 | 2010-11-04 | Travanti Pharma Inc | Abuse potential reduction in abusable substance dosage form |
| WO2010098261A1 (en) * | 2009-02-24 | 2010-09-02 | 久光製薬株式会社 | Risperidone-containing transdermal preparation and adhesive patch using same |
| JPWO2010098261A1 (en) * | 2009-02-24 | 2012-08-30 | 久光製薬株式会社 | Risperidone-containing transdermal absorption preparation and patch using the same |
| JP2013529100A (en) * | 2010-04-28 | 2013-07-18 | キンバリー クラーク ワールドワイド インコーポレイテッド | Injection mold microneedle array and manufacturing method thereof |
| US9545507B2 (en) | 2010-04-28 | 2017-01-17 | Kimberly-Clark Worldwide, Inc. | Injection molded microneedle array and method for forming the microneedle array |
| GB2485637A (en) * | 2010-11-22 | 2012-05-23 | Dewan Fazlul Hoque Chowdhury | Multi-layered Transdermal Patch activated upon removal of an impermeable inner liner |
| WO2012069820A1 (en) * | 2010-11-22 | 2012-05-31 | Dewan Fazlul Hoque Chowdhury | Multi-layered transdermal patch |
| JP2013023271A (en) * | 2011-07-25 | 2013-02-04 | Toppan Printing Co Ltd | Liquid applicator |
| US11129975B2 (en) | 2011-10-27 | 2021-09-28 | Sorrento Therapeutics, Inc. | Transdermal delivery of high viscosity bioactive agents |
| JP2014005219A (en) * | 2012-06-22 | 2014-01-16 | Teijin Ltd | Sheet-like hemostatic material |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3172395B2 (en) | 2001-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR950001971B1 (en) | Printed transdermal drug delivery device | |
| US4201211A (en) | Therapeutic system for administering clonidine transdermally | |
| US4262003A (en) | Method and therapeutic system for administering scopolamine transdermally | |
| US4031894A (en) | Bandage for transdermally administering scopolamine to prevent nausea | |
| US5006342A (en) | Resilient transdermal drug delivery device | |
| US4060084A (en) | Method and therapeutic system for providing chemotherapy transdermally | |
| US4698062A (en) | Medical device for pulsatile transdermal delivery of biologically active agents | |
| US5314694A (en) | Transdermal formulations, methods and devices | |
| US7247315B2 (en) | Compositions and medical device for transdermal delivery of a drug and methods of making and using same | |
| JP3523259B2 (en) | Plasters containing volatile active substances that can be produced without solvents | |
| AU3247193A (en) | Printed transdermal drug delivery device | |
| AU2002329763A1 (en) | Composition and transdermal drug delivery device | |
| JPS6049601B2 (en) | treatment device | |
| JPH08337521A (en) | Percutaneous drug-releasing device | |
| IL93678A (en) | Transdermal system exhibiting graduated drug release and its use | |
| US5176917A (en) | Transdermal system exhibiting graduated drug release and its use for the local or systemic administration of active substances | |
| KR20060123551A (en) | Transdermal delivery device for dihydropyridine type calcium antagonists containing at least one fatty acid | |
| KR910003107B1 (en) | Preparation for trans dermal permeation having ethylene-vinyl acetate matrix | |
| NZ240096A (en) | Fragrance releasing device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20010313 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |